Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9752W HIGH $7.91
Volume
2.53 K
Value Traded
26.76 K
Short % Float
0.1%
Days to Cover
1.0
-0.87%Week
-9.97%1 Month
+9.29%3 Month
-0.87%6 Month
-99.45%5 Year
-99.45%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.03 M
EPS (TTM)
-2.19
P/E Ratio
-
Ent. Value
-555.60 K
Total Shares
2.96 M
Float Shares
2.83 M
Insiders
4.34%
Institutions
6.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CDIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Cardio Diagnostics Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cardio Diagnostics Holdings Inc.
6Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
Event history 5
▲Manufacturing MilestoneCMC / Inspection
Launch of in-house CLIA-certified laboratory in Iowa City
▲Other Regulator MilestoneEx-US Regulatory
Secured out-of-state licenses from California, Maryland, Rhode Island, and Pennsylvania
▲Other Regulator MilestoneEx-US Regulatory
Received CLIA license after inspection with no deficiencies
Past FDA Catalysts and PDUFA Decisions
How CDIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Cardio Diagnostics Holdings Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CDIO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fung Peter KDirector | Grant/Award | 2,854 12,367 held | $2.19 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CDIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CDIO for Q2 2026. | ||||
CDIO Institutional Ownership Trends
CDIO Short Interest
Shares sold short, counted twice a month.
0.1%
Short % of Float
of tradable shares sold short
3.0K
Shares Sold Short
+193.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
31.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CDIO ranks across every disease it competes in
Competitive Position is a premium feature
See how CDIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCDIO News
CDIOCardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
Cardio Diagnostics has published a new rural health report focusing on cardiovascular care. The report emphasizes the growing gap in healthcare access in rural areas, particularly due to workforce shortages. It aims to raise awareness and stimulate discussions on improving cardiovascular care in these underserved regions.
Read more →CDIOCardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
Cardio Diagnostics has officially launched its in-house, high-complexity CLIA-certified laboratory located in Iowa City, Iowa. This facility is expected to enhance the company's operational capabilities and improve efficiency in test processing. The CLIA certification signifies that the laboratory meets high standards for clinical testing.
Read more →CDIOCardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
Cardio Diagnostics Holdings, Inc. has announced an upcoming investor conference call scheduled for August 20, 2026, at 3 p.m. Central Time. This event aims to engage with investors and provide updates on the company's progress and future plans. Such calls are typically intended to foster transparency and investor relations.
Read more →CDIO▼ -7.7%on this news
Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network
Atlas Healthcare Physicians will cover Cardio Diagnostics' precision cardiovascular medicine tests across its network. This partnership aims to enhance patient access to advanced cardiovascular diagnostics. The collaboration is expected to improve the quality of care provided to patients within the Atlas network.
Read more →CDIO▼ -6.3%on this news· ran to +127% by day 3
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
Cardio Diagnostics Holdings, Inc. will host an investor call on February 18, 2026, to discuss its precision molecular approach to cardiovascular disease. The call will cover updates on its tests, Epi+Gen CHD™ and PrecisionCHD™, along with recent clinical data and growth initiatives. Participants can join via telephone or webcast.
Read more →CDIOLeading the Next Frontier in Precision Cardiovascular Medicine 2026 NASDAQ: CDIO 1 Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of the Priv
Cardio Diagnostics Holdings, Inc. is at the forefront of precision cardiovascular medicine, showcasing its innovative solutions powered by epigenetics and artificial intelligence. The company aims to enhance early detection and prevention of cardiovascular diseases, presenting a comprehensive growth strategy with a robust intellectual property portfolio. With a significant total addressable market and a leadership team experienced in diagnostics and AI, Cardio Diagnostics is positioned for growth amidst the ongoing challenges of cardiovascular health. The potential future impact includes not only improved patient outcomes but also a reduction in healthcare costs associated with heart diseases.
Read more →CDIO▼ -47.1%on this news
Cardio DIAGNOSTICS HoldingS, INC. ANNOUNCES 1-for-30 reverse stock split
Cardio Diagnostics Holdings, Inc. has announced a 1-for-30 reverse stock split of its common stock, effective from May 13, 2025. This action comes as part of the company's strategy to regain compliance with Nasdaq's minimum bid price requirements. Following the split, the number of outstanding shares will decrease significantly, from approximately 52 million to about 1.7 million shares. While this move could stabilize the stock price, it also reflects underlying financial pressures within the company.
Read more →CDIO▲ +7.1%on this news
COMPANY UPDATE Revolutionizing Cardiovascular Medicine With Epigenetics and AI Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of t he Private
Cardio Diagnostics Holdings Inc. has announced key developments aimed at revolutionizing cardiovascular medicine through the integration of epigenetics and artificial intelligence. The company emphasizes the significance of forward-looking statements in their approach, highlighting a commitment to innovation within the sector. With these advancements, the company positions itself as a leader in combining cutting-edge technology with healthcare solutions.
Read more →CDIO▼ -25.9%on this news
COMPANY UPDATE Revolutionizing Cardiovascular Medicine With Epigenetics and AI MARCH 2024 Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of t
The recent company update highlights advancements in cardiovascular medicine through the integration of epigenetics and artificial intelligence. The presentation conveys a commitment to innovative medical solutions that may enhance treatment options. Additionally, forward-looking statements imply potential developments on the horizon, positioning the company favorably within the biopharma sector.
Read more →CDIOCardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement CHICAGO
Cardio Diagnostics Holdings, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. Following a previous notification of non-compliance, the company successfully maintained a closing bid price of $1.00 or higher for ten consecutive business days. As a result, Nasdaq has confirmed that Cardio Diagnostics can continue its listing on the Nasdaq Capital Market, categorizing the matter as closed.
Read more →CDIO▼ -8%on this news· ran to -30% by day 3
Cardio Diagnostics Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million CHICAGO, IL
Cardio Diagnostics Holdings, Inc. has announced a financing agreement with Yorkville Advisors Global, LP for up to $11.2 million. The Company will issue convertible debentures, with the initial closing providing $4.5 million. These funds are intended to accelerate the adoption of their PrecisionCHD and Epi+Gen CHD clinical tests and support further development of new tests. The CEO highlighted the potential impact of this investment on enhancing heart disease prevention and early detection efforts.
Read more →CDIO▼ -10.4%on this news· ran to -39% by day 3
shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K")filed with the Securities and Exchange Commission (the "SEC") on
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL Capitalized terms used but not defined in this Exhibit 99.1 shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K")filed with the Securities and Exchange Commission (the "SEC") on October 31,
Read more →CDIOMana Capital Acquisition Corp. Announces Intention to Further Extend Period to Consummate Initial Business Combination Dover, DE
Mana Capital Acquisition Corp. Announces Intention Further Extend Period to Consummate Initial Business Dover, DE, September 22, 2022-Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) (the "Company" or "Mana Capital") today announced that its Board of Directo
Read more →CDIOCardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease CHICAGO, Ill - Cardio Diagnostics, Inc. ( Cardio Diagnostics or the Company ), a pi
Diagnostics Announces Issuance of U.S. Patent for and Methods for Detecting Predisposition to Cardiovascular Disease CHICAGO, Ill - Cardio Diagnostics, Inc. ("Cardio Diagnostics" or the "Company"), a pioneering precision cardiovascular testing company, today announced that th
Read more →CDIOTransforming Cardiovascular Cardiovascular Health Through Our AI - Driven Integrated Genetic - Epigenetic Epigenetic Engine INVESTOR PRESENTATION August 2022 MANA CAPITAL Acquisition Corp. Disclaimer General This present
Transforming Cardiovascular Cardiovascular Health Through Our AI - Driven Integrated Genetic - Epigenetic Epigenetic Engine INVESTOR PRESENTATION August 2022 MANA CAPITAL Acquisition Corp. Disclaimer General This presentation is for informational purposes and only to assist in e
Read more →CDIOMana Capital Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination Dover, DE
Mana Capital Acquisition Corp. Announces Intention Extend Period to Consummate Initial Business Combination Dover, DE, August 23, 2022-Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) (the "Company" or "Mana Capital") today announced that its Board of Direct
Read more →CDIOMana Capital Acquisition Corp. and Cardio Diagnostics, Inc. Announce Definitive Business Combination Agreement to Create Publicly Listed Company Set to Transform Cardiovascular Disease Through Epigenetics Cardio Diagnost
Capital Acquisition Corp. and Cardio Diagnostics, Inc. Definitive Business Combination Agreement to Create Listed Company Set to Transform Cardiovascular Disease Cardio Diagnostics, Inc. has pioneered a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic E
Read more →CDIOMana Capital Acquisition Corp. Announces the Separate Trading of its Common Stock, Warrants and Rights, Commencing
Mana Capital Acquisition Corp. Announces the Separate Trading of its Common Stock, Warrants and Rights, Commencing Dover, DE - January 12, 2022 - Mana Capital Acquisition Corp. (Nasdaq: MAAQU) ("Mana" or the "Company"), today announced that, commencing January 14, 2022, hold
Read more →CDIOMANA CAPITAL ACQUISITION CORP. BALANCE SHEET Actual as of
MANA CAPITAL ACQUISITION CORP. Actual as of November 26, 2021 Pro Forma Adjustments As Adjusted (Unaudited) (Unaudited) ASSETS Current Assets Cash $ 887,872 $ (60,000 ) $ 827,872 Prepaid Expenses - short term 199,725 - 19
Read more →CDIOINDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of Mana Capital Acquisition Corp.: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
Page Audited Financial Statement of Mana Capital Acquisition Corp.: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of November 26, 2021 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Shareholders an
Read more →About Cardio Diagnostics Holdings Inc.
Headquarters311 W. SUPERIOR STREET, CHICAGO, IL, 60645
BIOPHARMAWATCH ELITE PLUS
Trade the next CDIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime